Ancuta, C

de la Vega, MC

Gordeev, AV

Jankova, R

Kalyoncu, U

Kawakami, A

Lagunes, I

Morovic-Vergles, J

Nagy, O

Peixoto GU e Silva de Souza, M

Rojkovich, B

Sidiropoulos, P

Taylor, P

Taylor, Peter

de la Vega, Mc

Gordeev, Av

Oxford University Research Archive

EULAR20 || SENSE RA encore || due Jan. 31 2592/3600 characters Title: Treatment satisfaction, expectations, patient preferences and characteristics, including digital health literacy (DHL), and the impact of suboptimal disease control in a large international cohort of patients with rheumatoid arthritis (RA): The SENSE study  Authors: Taylor PC,1 Ancuta C,2 Nagy O,3 de la Vega MC,4 Gordeev AV,5 Jankova R,6 Kalyoncu U,7 Lagunes I,8 Morovic-Vergles J,9 Peixoto GU e Silva de Souza M,10 Rojkovich B,11 Sidiropoulos P,12 Kawakami A13 Affiliations: 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,  University of Oxford, Oxford, UK 2Department of Rheumatology, “Grigore T. Popa” University of Medicine and Pharmacy, Iași, Romania 3AbbVie Ltd, Budapest, Hungary 4CEIM Investigaciones Medicas, Buenos Aires, Argentina 5V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation 6Department of Rheumatology of Children and Adults, Motol Teaching Hospital, Prague, Czech Republic 7Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey 8AbbVie Inc., North Chicago, IL, United States 9Division of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, University of Zagreb School of Medicine, Zagreb, Croatia 10Santa Casa de Belo Horizonte, Belo Horizonte, Brazil 11Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, Hungary 12Faculty of Medicine, University of Crete, Heraklion, Greece 13Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences,  Nagasaki, Japan Corresponding author: Prof Peter Taylor, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Headington, Oxford, UK. Tel: +44 (0)1865 227323. Email: peter.taylor@kennedy.ox.ac.uk Background: Patient characteristics, their treatment preferences and goals are important determinants of treatment success in rheumatoid arthritis (RA). Objectives: SENSE study aimed at assessing the impact of inadequate response to disease-modifying anti-rheumatic drugs on disease outcomes, and analyze their attitude their treatment and disease.  Methods: Non-interventional, cross-sectional study conducted in 18 countries in Europe, Asia, and America. Adult RA patients with moderate/high disease activity were eligible. Patient satisfaction was assessed by Treatment Satisfaction Questionnaire for Medication, Version 1.4 (TSQM v1.4). Treatment adherence, patient preferences, and expectations were evaluated by visual analog scale. eHealth Literacy Scale was employed for evaluating DHL. Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis, v2.0 (WPAI-RA) was used to assess workability and patient documentation for healthcare resource utilization (HRU). Results: 1624 patients were included in this analysis; most were female (84.2%), middle-aged, and had a mean (standard deviation [SD]) disease duration of 10.5 (9.3) years. 11.9% of the patients had retired early and 6.0% were unemployed due to RA. Mean (SD) total WPAI-RA score was 55.1% (26.7). In the previous 3 months, the mean (SD) number of healthcare professional and emergency room visits were 2.2 (2.5) and 1.6 (1.3), respectively. Mean (SD) TSQM v1.4 global satisfaction subscore was 60.9 (20.9), with only 13.5% reporting good treatment satisfaction (TSQM global ≥80). The leading treatment expectations were ‘general improvement of arthritis’, ‘less joint pain’, and ‘lasting relief of RA symptoms,’ with mean (SD) scores of 5.7 (1.6–1.7) for each. 60.7% of patients preferred oral administration and 31.3% preferred not to use drug combinations for RA. Preferred time to effect was predominantly ‘up to one week’ (71.1%). Least frequently side effects rated ‘acceptable’ were ‘increased risk for malignancies’ (3.5%) and ‘increased risk for cardiovascular diseases’ (3.3%). Most patients (67.4%) had poor DHL. Good adherence (in 87.4% of patients) was significantly associated with lower levels of joint pain.  Conclusions: Suboptimal disease control has a significant impact on satisfaction, workability, and HRU. Our results can support shared decision-making when setting RA treatment strategy.  Acknowledgments: AbbVie Inc. was the study sponsor, contributed to the study design, data collection, analysis and interpretation, and to writing, review, and approval of the final version. Medical writing support was provided by Russell Craddock, PhD and John Ewbank, PhD, of 2 the Nth (Cheshire, UK), and was funded by AbbVie.

English

Treatment satisfaction, expectations, patient preferences and characteristics, including digital health literacy (DHL), and the impact of suboptimal disease control in a large international cohort of patients with rheumatoid arthritis (RA): The SENSE study

Treatment satisfaction, expectations, patient preferences and characteristics, including digital health literacy (DHL), and the impact of suboptimal disease control in a large international cohort of patients with rheumatoid arthritis (RA): The SENSE study

Abstract

Similar works

Full text

Available Versions

Oxford University Research Archive